Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan.
Allergol Int. 2013 Mar;62(1):131-5. doi: 10.2332/allergolint.12-OA-0482. Epub 2013 Jan 25.
Nebulized drugs for asthma treatment are often mixed together in order to simplify inhalation regimens, although not recommended. We therefore evaluated aerosol characteristics and physicochemical stability of the admixture of an inhaled corticosteroid suspension with a beta2-agonist solution.
An 8-stage cascade impactor was used to measure the particle size distribution of admixture of Pulmicort® Respules® (budesonide, 0.5mg/2mL) with Meptin® Inhalation Solution Unit (procaterol hydrochloride, 30μg/0.3mL) from a jet nebulizer, PARI LC Plus®. Concentration of each drug was assayed with high-pressure liquid chromatography. Physicochemical compatibility was also assessed up to 24 hours after mixing.
With regard to budesonide, impactor parameters such as mass median aerodynamic diameter (MMAD) and respirable mass (RM) were comparable between admixtures and single-drug preparations (2.92 ± 0.03 vs 2.99 ± 0.14μm, 146.8 ± 2.9 vs 147.6 ± 8.2μg, respectively). On the other hand, delivery rates of procaterol increased when admixed with budesonide suspension, resulting in significantly higher RM (15.1 ± 0.8 vs 10.2 ± 0.5μg, p < 0.01). Variations from initial concentration in the percentages of drug remaining at any time point were less than 10%, and there were no appreciable changes in pH of the admixtures for up to 24 hours.
There is a possibility that admixture might influence of aerodynamic characteristics of procaterol, but not budesonide. In vivo data will be needed for the clinical implications of our findings.
为简化吸入方案,常将用于哮喘治疗的雾化药物混合使用,但这种做法并不推荐。因此,我们评估了吸入性皮质激素混悬剂与β2-激动剂溶液混合后的气雾剂特性和物理化学稳定性。
采用 8 级雾化撞击器测量了由 PARI LC Plus®(喷射式雾化器)雾化普米克令舒®(布地奈德混悬液,0.5mg/2mL)和博利康尼®雾化溶液(盐酸丙卡特罗,30μg/0.3mL)得到的混合物的颗粒大小分布。采用高压液相色谱法测定各药物浓度。混合后 24 小时内还评估了物理化学相容性。
就布地奈德而言,撞击器参数(如质量中值空气动力学直径(MMAD)和可吸入质量(RM))在混合物和单药制剂之间无显著差异(分别为 2.92 ± 0.03μm 对 2.99 ± 0.14μm,146.8 ± 2.9μg 对 147.6 ± 8.2μg)。另一方面,布地奈德混悬液与盐酸丙卡特罗混合后,其药物输送率增加,导致 RM 显著增加(15.1 ± 0.8μg 对 10.2 ± 0.5μg,p<0.01)。在任何时间点,药物残留百分比的初始浓度变化均小于 10%,混合液的 pH 值在 24 小时内无明显变化。
混合可能会影响盐酸丙卡特罗的空气动力学特性,但对布地奈德无影响。我们的研究结果对临床的影响还需要体内数据来证实。